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1.  Introduction 
 
In last two decades firms from emerging countries such as India and China have 
dominated the production of active ingredients in pharmaceutical industries all over the 
world. Until recently firms from these countries were struggling to reverse engineer 
complex and expensive biologic products which are increasingly used to treat cancer, 
diabetes and other diseases. Biologics are a therapeutic drug category comprising large 
complex molecules such as growth factors, cytokines, hormones, monoclonal antibodies 
and vaccines. However, some pharmaceutical firms have developed capabilities to 
reverse engineer these biological products which have been termed ‘Biosimilars’. Thus 
Biosimilars (also known as biogenerics or follow-on biologics) are biotech drugs that 
have been shown to have comparable quality, efficacy and safety to an original biologic 
product (Krull, and Rathore, 2010). This rise of biosimilars and capabilities for cheap 
production in developing country firms has potential to disrupt current market structure 
and transform patient care in developing countries as well as advanced countries. As 
biologic products begin to come off-patent, a market is emerging for biosimilars – 
copycat products produced at lower prices. It has been estimated that sales worldwide of 
biologics in 2009 reached $130 billion (Manufacturing Chemist, 2010) and that 
biosimilars might offer reductions of up to 30% compared to an original biologic (Krull 
and Rathore, 2010; Iskowitz, 2010). This emergence of a new market dynamic is 
disruptive to current key players as it has potential challenge their current dominant hold 
over the market, while for firms from developing countries it creates a sea of 
opportunities. The potential to generate considerable cost savings for governments and 
health care systems has been widely commented on. Potential for saving of course 
depends on the willingness of existing and emerging suppliers to compete in the market 
to innovate and develop biosimilars and a well-established regulatory framework. Thus 
emergence of biosimilars has become a contentious issue and has led to debate among 
key industry players, non-governmental organisations and leaders of developed and 
developing countries (Harris, 2011).    
 
Biosimilars are distinct from generics and as such, the sector deserves separate 
analysis. As large complex molecules, derived from specific cell lines, biologics are 
difficult to produce with consistency (Agres, 2011). Even if the formulation and 
production process is known, biosimilars as generic versions of a biological, cannot be 
identical to a reference biologic. Any small difference in the manufacturing process, input 
or purification procedure can result in a molecule significantly different in terms of 
efficacy and immunogenicity. This paper reviews study data collected at Innogen and the 
most recent literature to understand how the sector for biosimilars is evolving and the 
opportunities and challenges faced by emerging suppliers. The aim of the paper is to 
identify the gaps in the current literature and opportunities for further study in this area. 
Our analysis suggest that much of literature on biosimilars is focused on issues related 
to the development of governance mechanisms and potential market opportunities. 
Absent from the literature is any analysis of the evolution of firm level capabilities and 
policy frameworks that balance the needs of innovator and imitator firms without 
comprising affordable healthcare for poor people.   
 
Section two of this paper describes the background of the biosimilar segment in 
biotechnology broadly covering size and growth of the market sector and the 
opportunities for emerging suppliers. Section 3 explains the methods used to identify the 
most recent literature and the study of Indian pharmaceutical companies conducted in 
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2010. In section 4 we examine the challenges and drivers of biosimilar development, 
including now directions in innovation and the limitations posed by patents and data 
exclusivity. Section 5 re-examines data collected for an Innogen study on Indian 
pharmaceutical companies and suggests what capacity exists for biosimilar 
development. In section 6 we conclude by highlighting the gaps in the current literature 
and the opportunities for further study.   
 
2. Background    
 
The potential for biologics in the treatment of existing and neglected disease is 
increasing as the blockbuster model in pharmaceuticals is gradually eroded and the role 
of biotechnology in drug development becomes more important(Chataway et al, 2007; 
Mittra, 2008; Tait and Mittra 2004) The growth of biologics is in fact, outstripping that of 
conventional pharmaceuticals (Mahler and Gray, 2011). Therapeutic biologics such as 
genetically engineered recombinant proteins and monoclonal antibodies now represent a 
large portion of newly approved therapies for conditions such as chronic inflammatory 
diseases and cancer (Kozlowski et al, 2011). A large number of biologics are 
approaching patent expiry, creating room for biosimilars (Wechsler, 2011; Mahler and 
Gray, 2011; Lee et al, 2011). 
 
The cost of drugs in all countries represents a large fraction of the total health care bill. 
Sponsors claim that they will be able to market biosimilars at discounts of 25 to 30 
percent off branded products. This may not be as much as the fall seen in the small 
molecules  generic market (Krull and Rathore, 2010; Iskowitz, 2010), but payers say that 
prices that are just 10 percent lower will be able to gain market share and will represent 
a significant cost saving for patients in both regulated, and less regulated markets 
(Wechsler, 2011; Selz, 2010). For example, in a study in 2008, the German R&D 
institute for healthcare, IGES, identified potential savings of more than Euro 8bn by 2020 
in Germany if biosimilars were to be prescribed. Another study has suggested that as 
much as $2 billion can be saved by the European healthcare providers by just the first 
wave of biosimilar products (O’Donnell, 2006 cited by Krull and Rathore, 2010). In the 
US, savings in the high double-digit billions range are expected over a 10-year period 
(Ellis, 2010). According to the Congressional Budget Office, biosimilars may save 
consumers and health systems in the US as much as $25 billion over 10 years as newly 
approved biosimilars drive the prices of biological drugs downward. There is particular 
need to reduce the cost of drugs in cancer care which is a growing burden in many 
countries, and biologics show promise in this field (Cornes, 2011). One example here 
would be the HPV vaccine, used to prevent cervical cancer.  
 
Unlike the development of an originator biologic, the development of certain biosimilars 
is attached to a smaller risk in terms of demonstrating safety and efficacy. If a biosimilar 
has a reference product with many years of data, production and market experience, 
and proven feasibility, the risks of developing a biosimilar are much more calculable. It 
should be an attractive opportunity for investment but the industry must have access to 
adequate capitalisation, which may prove to be an issue in low and middle income 
countries (Selz, 2010). It is important however, to consider that the cost of development 
and manufacturing for many biosimilars would still be quite high. 
 
Finally, we look at cost. The Pharmaceutical Research and Manufacturers of America 
(PhRMA) estimate it costs in the region of $1.2 billion to develop a new biologic 
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compared with approximately $375 million for a biosimilar (this depends on the type of 
biosimilar as costs varying significantly. These figures are more likely to apply to 
conventional biosimilar therapies and will exclude for example, cell therapies). Time lines 
for development, compared to a novel biologic are also considerably shorter, as there is 
no need for a Phase ll programme and Phase I and Phase III can often be truncated 
(Watson et al 2010). 
 
2.1 Size and growth of the market 
 
There have been numerous and wide ranging estimates for the size and growth of the 
market in biosimilars. While some suggest growth reaching multi-billion dollar levels 
within five years, others argue that biosimilars will never be a threat to branded biologics 
(Biomedical Market Newsletter, 2011) due to the complex nature of production and 
limited scope for proving similarity to a reference product (see below).   
 
In 2009, sales of biologics reached $130 billion (Manufacturing Chemist, 2010). While 
this represents a fraction of total drug sales, the market for biologics is growing and 
recent industry predictions are that biopharmaceuticals will soon make up 50% of new 
drug approvals (Fernandez, 2010). In the four and a half years prior to late 2010, there 
were 58 approvals within the European Union and/or the United States, of which about 
40% (25) were new biologics; and around 50% of the remaining approvals (28) were 
biosimilars and reformulated existing products. Monoclonal antibodies are the most 
rapidly growing class of biologic medicine, with over 40 per year entering clinical trials 
since 2007 (Mahler and Gray, 2011). A 2010 report by URCH publishing suggests that 
biosimilars could account for 2.6% of the biologics market by 2016 (Manufacturing 
Chemist, 2010). 
 
A 2010 report by BioPortfolio estimated that the global biosimilars market would be worth 
$19.4 billion by 2014, growing at an expected compound annual growth rate of 89.1% 
from 2009 to 2014 (Ariyanchira, 2010). This report was superseded by a more 
conservative estimate in 2011 of a worldwide market valued at $3.7 billion by 2015, up 
from about $250 million last year (Datamonitor, 2011 cited by Wechsler, 2011; Sutton, 
2011). 
 
The main companies with existing capabilities in biosimilars include: Merck, Sandoz 
(Germany, the generics arm of Novartis), Teva (Israel), Hospira (US), Dr. Reddy's 
Biocon Ltd. (India), Biopartners GMBH (Switzerland), Cipla Ltd. (India), Intas 
Biopharmaceuticals Ltd. (India), Shantha Biotechnics Ltd. (India) and Wockhardt Ltd. 
(India) (Biomedical Market Newsletter, 2011, 2011b). A number of companies are 
entering into strategic partnerships with biotechnology companies in order to acquire 
capabilities in biosimilar production. In October 2010, Pfizer announced a deal to work 
with Biocon (India’s biggest biotech company) to bring a biosimilar insulin treatment to 
market (Economist, 2010). In January 2011 Parexel and Merck announced their alliance; 
Parexel will bring regulatory and clinical development planning to Merck BioVentures, 
which has a goal of five potential biosimilar products in late-stage clinical trials by 2012. 
There are further reports of planned activity. Amgen for example is reportedly 
considering biosimilars particularly in emerging markets like Asia and South America and 
the CEO of Biogen has suggested the company is in a prime position to develop 
biosimilars because of its manufacturing and expertise in biologics (Henderson, 2011). 
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The global distribution of key and niche players has been sketched as shown in table 1. 
At this early stage the prominence and potential of producers in the Asia Pacific is clear.  
 
Table 1. Distribution of key and niche players in 2011 
 
Region/Country No. of key & 
niche players 
The United States 11 
Canada 2 
Europe 16 
France 1 
Germany 10 
The United Kingdom 2 
Rest of Europe 3 
Asia-Pacific (Excl. 
Japan) 
28 
Latin America 1 
Africa 1 
Middle East 2 
   (adapted from Biomedical Market Newsletter, 2011b) 
 
2.2  Opportunities for emerging suppliers  
 
There is considerable biologics R&D and commercial activity in the emerging markets of 
the BRIC countries (Brazil, Russia, India and China) and the Asian Pacific Rim region. 
The most obvious reason is cost arbitrage. In India for example, the cost of developing a 
biosimilar molecule requires an investment of about $10 to $20 million, as compared to 
$50 to $100 million in developed countries (Frost and Sullivan, 2011) (or even $375 
million as quoted by other authors).  
 
Existing biosimilar producers are well-positioned to take advantage of predicted market 
growth because they already have an industry reputation and relationships with key 
stakeholders. However, branded pharma companies may also be looking to enter the 
biosimilars arena as a way of increasing sales. As described above, partnerships and 
mergers and acquisition are potential ways of achieving this (Sutton, 2011), possibly 
providing opportunities for emerging suppliers. Samsung along with other South Korean 
based electronics firms has announced its intention to enter the biologics market with a 
$389 million investment in 2009. In 2011 Samsung entered into a partnership with 
Quintiles (a $266 million venture) to start producing biosimilars in 2013 (Hoffman, 2011). 
Nair (2011) reports the partnering of Indian pharmaceutical firms with global 
manufacturers for the marketing of biosimilars. For example, India based Biocon India 
Ltd has partnered with Pfizer for the commercialisation of several insulin products.  
 
As discussed above, biosimilar manufacture requires substantial investment in 
equipment, technology, materials and personnel. Manufacturers with biosimilar drug 
candidates are increasingly turning to contract manufacturing organizations (CMOs) and 
clinical research organizations (CROs) worldwide that offer the proficiency, staffing, and 
state-of-the-art technology for developing and validating analytical methods, preclinical 
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and clinical development strategies, and bio-manufacturing processes (Freitag and 
Egan, 2011; Henderson, 2011; Fernandez 2010). Again, India has upcoming CRO’s 
which would add to Indian capabilities in biosimilars (Frost and Sullivan 2011).   
 
Government policies to facilitate the growth and survival of emerging suppliers can be 
influential. Samsungs investments for example, dovetail with South Korean government 
initiatives that aim to develop the country’s biosimilar industry (Hoffman, 2011). 
 
Internationally also there is a growing imperative for organisations such as the World 
Health Organisation and the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH), to foster a more 
consistent global regulatory landscape for biosimilars (Mahler and Gray, 2011).  
 
Emerging markets present not only an environment for the growth of industry, but also a 
consumer market. The middle classes in the less regulated developing countries, with 
increasing purchasing power and preference for state of the art goods and services, in 
the near future may provide a larger consumer market than developed countries (Selz, 
2010).  
 
Future regulatory change may open up opportunities for firms with competence and 
capability in the manufacture and regulatory approval procedures for biologics. For 
example, as of 2020, in the US, proteins will no longer be regulated as drugs, but as 
biologics. The expertise held by emerging suppliers or CRO’s may be gainfully employed 
by firms with biosimilar or biologic candidates in their pipelines. 
  
3. Research Methods 
 
3.1 Literature review 
 
Articles for this review were found using the EBSCO database. EBSCO includes 
Academic Search Complete, Business Source Complete, CINAHL, EconLit, EDS 
Foundation Index, Medline, Regional Business News and eBook Collection. The 
database was searched using “biosimilar” [or] “Follow on Biologic” in the title fields. The 
search yielded 981 articles. After removal of duplicates and articles relating to technical 
medical information on biologics, 397 articles remained.  
 
Of the 397 articles on biosimilars and follow on biologics, overwhelmingly, the large 
number focused on regulatory development, mostly in the US. To understand the 
contribution thus far to the research questions posed, articles were removed on the 
following subjects: clinical development of biosimilars; applicability of biosimilars to 
particular medical fields (e.g. oncology, dermatology); regulation and regulatory 
harmonisation (where the article exclusively reported on the progress made by the FDA); 
safety of biosimilars and standards; legal considerations; uptake of biosimilars by 
pharmacies/practitioners; news on specific manufacturers and product approvals. This 
left 93 articles on the subjects of the biosimilars market; economic impacts; industry 
perspectives; global development; data exclusivity and patent rights.  
 
Of the 93 articles of interest, most were short articles and news items published in 
periodicals, 22 were longer articles consisting of more than 5 pages and 2 were grey 
literature sources. A small number of articles (<5) were not available in full text. Table 2 
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shows the distribution of articles by year of publication, illustrating the growing interest in 
biosimilars. There were no articles in this search published before 2006. A summary of 
the most recent information on biosimilars is presented below. The summary is 
constructed primarily using articles from 2011 and 2010, utilising the most recently 
published articles first, and discarding earlier articles where information has been 
repeated or superseded by newer data.  
 
Table 2 Articles published each year on the biosimilars market and economic 
aspects of biosimilars 
 
Year 20111 2010 2009 2008 2007 2006 
No of 
articles 
20 21 22 17 7 6 
 
 
3.2 Data collection on Indian pharmaceutical companies  
 
In the case of the Indian pharmaceutical industry, secondary data was collected from 
annual reports, business magazines and consultancy reports. Annual Report present 
detailed information regarding a firm’s activities and collaborations which was cross 
checked with information with business magazines and consultancy reports.  Primary 
data was collected from interviews with biotech R&D heads in the Indian pharmaceutical 
firms such as Wockhardt and Dr.Reddy’s Laboratories.  
 
4.  Challenges in biosimilar capability development   
 
4.1 Firm level challenges in managing R&D and Manufacturing complexities  
  
The cost of a biosimilar compared to an originator biologic may be smaller, but the cost 
of manufacturing a biotech product is approximately 5-10 times more than that for a 
small molecule product (Krull and Rathore, 2010). A small molecule generic costs 
between $1.5 million and $4 million to develop (Watson et al., 2010), whereas 
developing a biosimilar can cost between $75 million and $375 million and typically 
takes seven to eight years (Wechsler, 2011). High operating costs as well as larger 
capital investments associated with manufacturing of biosimilars (compared to 
development and production of small molecule products) are attributed to a number of 
factors. Krull and Rathore report high costs because of i) Complex manufacturing 
processes and inputs where a small change in process can lead to significant change in 
the efficacy of a biologic or immunogenicity; ii) The complexity of the biologic product 
which means that analytic tools alone cannot completely predict the behaviour of large 
complex molecules in the clinic; iii) Complex feed materials which can be 
uncharacterised and will impact on process consistency and quality; iv) Lack of 
understanding of the relationship between product and process demonstrated by  
unknown correlations between the clinical safety and efficacy of a biotech product and 
its product quality attributes generally. The complexities and unknowns have led some 
authors to suggest that greater consideration will need to be given to clinical trial design, 
                                            
1
 Data collected up to August 2011. It is expected that by the end of 2011, this number will have exceeded 
the number of articles published in 2010. 
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target population and endpoint criteria for establishing equivalence. The trial must also 
be sensitive enough to detect any clinically meaningful differences. Therefore, the size of 
the trial may need to be even larger than that for the reference product in order to prove 
therapeutic equivalence with confidence (Watson et al, 2010), thus contributing to higher 
costs. In addition, in some markets such as Europe there is greater cost imposed by the 
regulatory authority (in this case, the EMA) for the requirement for long term post market 
safety monitoring (Schellekens, 2010).  
 
The challenges are different, depending on whether a firm is an innovating biologics firm, 
switching to biosimilars, or a traditional generics manufacturer, entering into biologics 
production for the first time. For innovating manufacturing firms, a shift of focus from 
innovation to replication is required. This means companies must develop strategies to 
transform expensive development and manufacturing processes into lean analogs.  
They would have to reduce the cost per unit dose and make the same amount of drug 
with fewer batches through higher fermentation titers, higher purification recoveries, and 
longer shelf-life formulations. A different set of challenges is faced by generic 
manufacturers. They will need the expertise to reverse-engineer the biologic and to 
develop a stable, therapeutically active cell line. They also will need to develop 
manufacturing processes to meet specifications, predictably and consistently while 
applying specialized analytical tools. They will also need to invest in new infrastructures 
for controlling living cells, purification, and producing biologic products at commercial 
scale, consistently. New infrastructures and capital investment include bioreactors, 
purification suites, fillfinish operations, sterile environmental controls, and systems that 
are more liquids than solids-based. To ensure stability during production, storage, and 
shipping, generic-drug companies must be able to characterize and mitigate the risk of 
degradation mechanisms of complex biologics. They also must avoid long development 
times to maintain the revenue and market share advantages that first-to-file status 
provides. Equivalency standards will have to be closely adhered to, as even small 
differences between the biosimilar and the reference product (e.g. binding, activity, 
posttranslational modification, impurity profiles, and stability) can affect bioequivalence 
and put regulatory approval at risk (Lee at al, 2011). 
 
The high cost of entry means that only those companies that are willing to absorb the 
costs and risks of development, registration and commercialisation will emerge as 
competitors (Greenland, 2010). The implications are that adequate capitalisation is 
essential for emerging suppliers and the role of partnerships, mergers and acquisitions 
will become more important. In the latter case particularly, the sector will continue to be 
dominated by a few large firms, mirroring perhaps the evolution of the vaccine industry.  
 
Because biosimilars will have to demonstrate equivalence in its safety and efficacy 
profile with an originator drug, the main positive differentiator will be price. Competition 
on price alone may then erode margins for all supply side participants (Szymkowski, 
2010; Selz, 2010). Industry commentators such as Selz (2010) argue this might not be 
sustainable.  However, this might be a driver of innovation, if biosimilar companies 
innovate to create differentiation for their products based on optimised formulation, 
delivery modes, packaging variants or service aspects for example (Selz, 2010).  
 
Selz (2010) suggests that uptake in the health care community may be limited by the 
scepticism displayed in reaction to the relatively fewer number of years of clinical 
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experience for each biosimilar, compared to the originator drug. This may outweigh the 
price advantage offered by a new biosimilar.  
 
Lastly, originator drugs, although they eventually will come off-patent, are protected by a 
number of “IP walls”. IP is used not only to protect the formulation, but also the upstream 
and downstream processing elements and the analytical methods. The prospect of long, 
risky and costly patent litigation might be too heavy a burden for small biosimilar 
producers to consider (Frost and Sullivan 2011; Selz, 2010).  
 
4.2 Directions in innovation  
 
Regulatory requirements to demonstrate comparability with the innovator biologic has 
placed a new emphasis on analytical techniques and methodologies, and has revealed 
the limitations of analytical methodologies as well as the need for new, more 
sophisticated techniques (Mahler and Gray, 2011). To address these requirements, new 
process analytical technologies (PAT) can be used to enhance predictability and 
understanding, thus minimizing batch rejections and increasing manufacturing run rates 
to produce batches more efficiently. Other innovative technologies, such as disposable 
single-use systems (e.g., bioreactors, media and buffer tanks, and drug-substance 
container/closure systems) might improve scalability and effectiveness. These 
technologies have the potential to lower production costs by reducing the number of 
product to- product and batch-to-batch changeovers and capital investments (Lee at al, 
2011). Generally the consensus in the industry is that lowering cost of goods for 
biologics will be driven principally through innovation in downstream processing (Mahler 
and Gray, 2011).  
 
Currently 60–70%of biologics are now produced in mammalian cells. There is a need for 
high yielding, transient expression systems. Progress in host cell engineering means that 
more stable cell lines can be generated compared to traditional amplified cell lines, and 
with more of a focus on product quality. Efforts are also being made to engineer cell lines 
with superior productivity characteristics (e.g., improved robustness, enhanced protein 
processing, and metabolic efficiency) (Mahler and Gray, 2011). 
 
Novel drug-delivery technologies could be another area of focus for innovator 
biopharmaceutical companies. These technologies could help to increase market share 
and provide a source of sustainable competitive differentiation (Lee at al, 2011). 
 
Biosimilar pipelines are rapidly shifting away from the initial focus on older, less complex 
biologics, towards the higher earning monoclonal antibodies as well as developing, 
“biobetters”. These are biologics, similar to an original product, but which offer 
improvements over the originator (Biomedical Market Newsletter, 2011).  
 
4.3 Regulatory quagmire  
 
The creation of a pathway for the approval of biosimilars has taken a long time (Agres, 
2011). The EU is considered to be ahead of the US in the development of its regulatory 
pathway. The European Medicines Agency (EMA), published general guidelines on 
biosimilars in 2005 and approved its first biosimilar in 2006. Fourteen additional 
biosimilars have since been approved by the EMA (Tzeng, 2010). Australia adopted the 
EU guidance in 2008, and the World Health Organisation finalisation of its own 
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guidelines is expected imminently. Numerous other countries have produced draft or 
final guidelines on biosimilars, including Canada, Malaysia, Turkey, Taiwan, Korea, 
Singapore, Argentina and Saudi Arabia (Ellis, 2010). In the US however, the FDA is 
experiencing difficulty as it grapples with the problems of meaningful difference and 
degree of comparability between a biosimilar and its reference biologic (Simoens et al 
2011). While guidelines for the US might be published this year, formal regulations might 
be some years away (DeArment, 2011). 
 
The recognised need to reduce the cost of drugs has led to The Affordable Care Act of 
2010 in the US which included the Biologics Price Competition and Innovation Act 
(BPCIA). This act authorised government agencies to establish an abbreviated 
regulatory pathway for approving biosimilars with an aim to reduce spending on 
prescription drugs.  Notwithstanding the complex situation in the US, regulatory 
authorities have begun to clarify their requirements for testing and approving biosimilars 
(Wechsler, 2011), better paving the way for their development. 
 
4.4 Patents and data exclusivity 
 
There is a significant difference between the position of the US and the position of 
regulatory agencies in the rest of the world (including the EU). EU guidelines 
acknowledge that biosimilars are different from their original reference product in terms 
of their raw materials and manufacturing processes, and that slight differences can 
significantly alter the safety and effectiveness of a biosimilar. Therefore, the EMA is 
using a case by-case approach, which requires comparability between the biosimilar and 
the innovator product to be justified by appropriate studies, such as clinical trials. 
Although European requirements for biosimilars are extensive when compared with 
small-molecule generics, they do not necessarily include full Phase III clinical trials in all 
cases and therefore can provide an abbreviated pathway for approval (Fernandez, 
2010). In July 2009, two US healthcare bills, the Biologics Price Competition and 
Innovation Act of 2007 and the Pathway for Biosimilars Act were proposed, containing 
adaptations of the Hatch-Waxman Act (which currently provides 5 years of data 
exclusivity for new chemical entities and new biological entities), to create an approval 
pathway for biosimilars (Grabowski, 2008; Tzeng, 2010). The two bills survived 
committee votes in US Congress and the Senate respectively before being reconciled 
and passed by the House of Representatives in March 2010 as part of the Healthcare 
Reform legislation. The legislation now stipulates that biosimilars must be subject to at 
least one clinical trial to demonstrate safety and efficacy. The new law guarantees 
manufacturers a period of 12 years exclusive market access for innovator biologics 
during which, the FDA cannot approve a product based on innovator studies2. 
                                            
2
 Further explained by Agres (2010) : “Part of problem is ambiguity in the law, which does not specify 
whether the 12 years of exclusivity refers to marketing or to protection of data. The U.S. Food and Drug 
Administration (FDA) is currently drafting a regulation that will answer that question as it outlines how the law 
will work in practice, including how much, if any, additional clinical testing will be required of generic 
applicants. Should the FDA decide that the law refers to data exclusivity, generic competitors will likely have 
to wait the full 12 years before gaining access to a reference drug’s underlying composition. They would 
then have to spend time developing a bioequivalent version before submitting an abbreviated approval 
application, giving the pioneer drug company months, if not years, of additional unencumbered sales. On the 
other hand, should the FDA interpret the law as referring to 12 years of marketing exclusivity, competitors 
might gain access to a pioneer drug’s underlying data in as few as four years after it had originally been 
approved. This would allow generic manufacturers time to develop a bioequivalent version and hit the 
ground running when the 12 years are up” (Agres, 2010). 
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Biosimilars sponsors also have to wait four years to even submit a 351(k) application to 
the agency following first licensure of a reference product (Wechsler, 2011). This 12-year 
protection for original biologics compares with only five years of protection for 
conventional drugs before generic versions appear. Currently, pioneer biological drugs in 
Europe are entitled to 10 years of data exclusivity before generic competition is allowed 
(Agres, 2011).  
 
On considering similar biological legislation in 2008, the Congressional Budget Office 
estimated that over 10 years, as much as $25 billion could be saved through its 
provisions for FDA approval of biosimilars by significantly driving reductions in the prices 
of biological drugs. However, when discussing the 12 year data exclusivity to innovator 
biologics manufacturers, the World Generic Medicines Congress (London, UK in 
February 2010), concluded that the extended exclusivity period has significant 
implications in delaying biosimilar development. Consequently, the provision is facing 
strong opposition from generics manufacturers and some politicians who argue that a 
shorter exclusivity period is necessary to make the development of biosimilars financially 
viable (Fernandez, 2010). The opposing side of the argument is of course, that sufficient 
time needs to be given for innovators to recoup the investments made to produce 
original biologics. Innovation in biologics has important benefits effecting overall social 
welfare as well as showing promise in specific areas such as cancer treatment 
(Grabowski, 2008). Grabowski (2008), in a portfolio study of new chemical entities 
between 1980 and 1984 demonstrates a mean break-even time of 16 years. Between 
1990 and 1994, this had decreased to 15 years. For biological entities, mean break even 
times vary in his model, ranging from 12.9 to 16.2 years, depending on the parameters 
used for calculation. While arguments exist that oppose such analyses, or the basis for 
cost estimates, the FDA remains under pressure to strike the appropriate balance 
between competition and innovation (Grabowski, 2008; Tzeng, 2010).  
 
5. The Indian pharmaceutical industry and capabilities for biosimilars 
 
In the last two decades the Indian pharmaceutical industry has emerged as a cheap 
supplier of drugs to the rest of the world.  Taking advantage of weak patent law 
introduced in 1970s by the Indian government, local firms used reverse engineering to 
develop cheap drugs, and as a consequence, extensive process R&D capabilities.  Post 
TRIPS agreement these firms entered generic markets in advanced countries and made 
a mark using their superior process R&D skills, cheap production processes and deep 
distribution and marketing capabilities (Kale, 2007).  Some Indian firms such as Cipla 
played a significant role in reducing prices of HIV cocktail drugs to poor populations of 
developing countries.  For example, in beginning of 2000 Cipla offered to sell HIV 
cocktail at less than 4 % of prices charged by MNC firms and forced these companies to 
reduce their prices for African country populations. Now Cipla is one of the world's 
largest producers of antiretroviral (ARV) drugs to fight HIV/AIDS. Estimate from few 
years ago indicated that 40 per cent of HIV/AIDS patients undergoing ARV therapy were 
using Cipla drugs (Sharma, 2011). 
 
Low-cost volunteers and strong clinical trial capabilities in the country have been the 
major cost-eroding factors for India. Building on this experience in the pharmaceutical 
generic industry in advanced countries, Indian firms are now targeting biological markets 
in developing as well as developed countries. Some of these firms have evolved 
capabilities for development and manufacturing of biosimilar products at much cheaper 
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rates and now trying to enter world market. India has in fact already introduced insulin 
and erythropoietin biosimilars, proving an ability to contribute to the market (Frost and 
Sullivan, 2011). 
 
The Indian Government is playing an important role in encouraging the biosimilar 
industry. Biotechnology parks are under construction in Hyderabad, Pune, and 
Bangalore which provide special tax incentives to participants to support cost 
containment (Frost & Sullivan 2011). The department of biotechnology in India is inviting 
proposals from Indian companies, working on biosimilars, under its biotechnology 
industry partnership program. According to the proposal, the Indian Government will 
provide support to biotech companies on a cost-sharing basis for development of novel 
and high-risk technologies and to enhance existing R&D capacities, specifically for 
biosimilars. Analysts recognise that the rate of growth in India and other countries, will 
be largely dependent on the transparency of approval processes and government 
support. To sell in Europe and the United States, emerging suppliers must have certified 
facilities with the FDA and the EMA. While the cost of compliance may be higher, this 
may enhance credibility in the biosimilar market (Frost and Sullivan 2011).   
 
The Indian pharmaceutical industry ranks 12th in the world in terms of value and is the 
second largest market in the world. Indian firms have traditionally focused on small 
molecules and chemistry dominated process R&D. However, in the post 1990 era some 
Indian firms entered the vaccine market and began investing in the development of 
biotechnology capabilities. Some of the early starters such as Wockhardt and Shanta 
Biotech developed collaborations with international research institutes and companies in 
order to develop vaccines for the domestic market.  
 
Ariyanchitra (2010) suggests that the Indian biosimilar market is worth around $200 
million and there are 7-10 companies that have developed capabilities in the 
manufacture of recombinant products. She further suggests that Indian firms have 
expertise in gene manipulation and fermentation but have recently invested in other key 
areas such as bioprocess development and cell-line development. One or two 
companies have generated their own clones and cell lines.  
 
Another significant challenge for Indian firms is accessing biosimilar markets in 
advanced countries as regulatory frameworks in the two most important markets of the 
world, theUS and Europe, are still at nascent stages of development. G.V.Prasad, vice 
chairman and CEO of DRL explains; 
 "It is a big game. It will cost at least $20 million to take a biosimilar drug to the European 
market. It takes only a small fraction of that amount for a conventional generics pharma 
product," (Suresh, 2008). 
 
However some Indian firms have made the move towards introducing biosimilar products 
in the Indian domestic market. Desai (2009) point out that more than 40 biologics are 
marketed in India, of which 25 are biosimilars and are manufactured locally while 
another 25 biosimilars are in the final stages of development.  Some of the products 
Indian firms are manufacturing include for example insulin, filgrastim, streptokinase, 
hepatitis B vaccine and rituximab. Table 3 provides details of leading Indian firms 
involved in the development of biosimilar products.   
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Table 3 Data of key Indian biosimilar players (Annual Reports, 2010) 
 
Firms Turnover 
Rs million 
Overseas 
Revenue 
Rs Million 
R&D intensity Target + current  
biosimilar portfolio 
DRL  74693 53340 (71%) 7% Filigrastim, 
Rituximab, 
pegfilgrastim 
Cipla 64830 35409 (55%) 4% Avastin 
(Bevacizumab, 
Herceptin 
(trastuzumab), 
Enbrel (etanercept) 
Biocon 28137 ~ 14068 
(50%) 
10% Human insulin, 
Insulin Glargine, 
Erythropoietin (EPO), 
Filgrastim (GCSF), 
Streptokinase, 
Monoclonal 
Antibodies 
Intas 15474.50  5321.02 
(34%) 
 Pegfilgrastim, 
Filgrastim, 
Erythropoietin, 
Recombinant 
Interferon Alfa-2b 
Wockhardt 37500.00 27000 (72%) 1.87% Human insulin, 
Monoclonal 
Antibodies, 
Erythroprotein, 
insulin glaritus 
 
 
Many of the companies license recombinant clones from CIGB in Cuba or other 
countries. Insulin, the Hep B vaccine, GM-CSF, and several other FDA-approved 
therapeutic products are manufactured using S.Cerevisiae. Since the introduction of 
these products from Indian companies, the cost of insulin and Hep B vaccine has 
dramatically declined in the Indian market, and now these products are widely available 
in India.  
 
5.1 Dr. Reddy’s laboratories (DRL) 
 
The most ambitious firm is possibly Dr. Reddy's Laboratories Ltd. (DRL) this 
pharmaceutical company is focusing on emerging markets such as India and Latin 
America. Their aim is to be one of the largest pharmaceutical firms in the world, 
competing with those like Roche, announcing plans to expand into biosimilars with an 
investment of 30 million dollars to improve research facilities (Dankekar, 2010). DRL 
launched its first biosimilar product, filgrastim in 2001 and following on that in 2007 the 
company launched its second product Reditux in the Indian domestic market.  
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In the last decade Dr. Reddy’s Laboratory (DRL) has consistently ranked amongst the 
top ten pharmaceutical firms in India.  Now the company has 15 manufacturing plants in 
India, 2 plants in UK and 1 in China. It has set up 23 subsidiaries for distributing and 
marketing pharmaceutical products in the domestic and international markets. DRL 
which started as a bulk drug manufacturer in the 1980s, moved to a formulation-
focussed company in the early 1990s, upgraded itself as a US focussed pharmaceutical 
company in the mid 1990s, and finally it is transitioning into ‘a research based 
international company’. Since the start of its operation DRL has continuously sought to 
move up value chain in terms of pharmaceutical products, markets and capabilities. Dr. 
Reddy’s laboratories (DRL), founded by Dr. Anji Reddy in 1984, has grown into a fully 
integrated pharmaceutical company with an annual turnover of Rs. 75,000 million in 
2010. 
 
In 2008 DRL made a mark in the biosimilars market by launching Rituximab used in the 
treatment of certain lymphomas, leukaemia’s and rheumatoid arthritis. In 2010-11, it 
grew by 75% over the previous year and emerged as the fifth largest brand in DRL’s 
product portfolio.  In 2010 Dr. Reddy’s launched the first generic Darbepoetin Alfa in the 
world for treating nephrology and oncology indications. In same year DRL also launched 
an affordable form of Pegfilgrastim, which is used to stimulate the bone marrow to fight 
infection in patients undergoing chemotherapy.  
 
According to its 2010 Annual Report, DRL has sold some 1.4 million units of its 
biosimilars, which have treated almost 97,000 patients across 12 countries.  
 
5.2 Intas 
 
Intas Biopharmaceuticals Limited (IBPL) was founded in 2000 as an independent 
biotechnology division of Intas Pharmaceuticals Ltd. Intas launched its first biosimilar 
product filgrastim (granulocyte colony-stimulating factor, G-CSF)  in July 2004,  followed 
by an erythropoietin injection in Aug 2005 and Interferon 2b in April 2007. Intas is 
focusing on developing biosimilars and second-generation products (superior generics) 
for the regulated markets of Europe and US after having established its presence in 
India and other semi-regulated markets. 
 
Intas Biopharmaceuticals Ltd signed an agreement with Canadian drug major Apotex Inc 
in May 2008, to co-develop and market the low-cost version of a biotech cancer 
medicine filgrastim (G-CSF) in North America and Europe and in January 2009 extended 
their agreement to develop a biosimilar version of pegfilgrastim. This collaboration gives 
Apotex the rights to market the product manufactured by Intas Biopharmaceuticals in 
North America, Europe and selected other countries. 
 
According to its 2010 annual report Intas is already present in around 70 semi-regulated 
markets and has plans to launch its entire range of biotech products in regions like 
South-East Asia, Latin America, CIS & Russia and Africa in the near future. Rustom 
Mody, chief scientific officer and director (Quality), IBPL explains Intas’s strategy for 
advanced markets such as Europe and USA; 
 "Our strategy would be a step-wise approach from active pharmaceutical ingredients 
(API) to biosimilars to contract research to collaborative research & bio-betters to novel 
INNOGEN Working Paper 94                                                             October 2011 
 
 
Farah Huzair and Dinar Kale 
 
 
16 
biologics. The company is aiming to replicate its biosimilar success of India and semi-
regulated markets in Europe & the UK".  
 
Intas Biopharma plans to invest about US$ 30 million to set up a new drug 
manufacturing facility dedicated to large-scale manufacturing of monoclonal antibody 
based products. Commercial production at the proposed facility is likely to commence by 
2011. 
 
5.3 Wockhardt 
 
Wockhardt Ltd was started by the Khorakiwala family in 1959 as a small pharmaceutical 
distribution and selling entity. The company set up its first formulation plant in 1977 and 
soon established a bulk drug plant in 1983. Now Wockhardt has 8 manufacturing plants 
in Aurngabad – 6 in the new biopharmaceuticals complex in addition to one each in 
Chikalthana and Waluj. In 1998 Wockhardt acquired Merind Pharma and became one of 
the largest producers of Vitamin B12 in Asia.  In 2004 Wockhardt commissioned a state 
of the art production facility dedicated to manufacturing only biotech products. The 
company went public in 1992 and in the same year started building biotechnology 
capability by hiring scientists from local R&D institutes and forming collaborations with 
overseas biotech firms. Dr. M.K.Sahib, head of biotech operations in 2004 explains the 
seeds of biotechnology capability development in Wockhardt; 
 
“I joined here in 1991-92 and came from CDRI. I had vast experience in the regulation of 
gene expression in mammalian systems as well as microbes and that helped me here…. 
we started here the recombinant area in collaboration with Rhein-biotech and we have 
today all the expression system that are approved for the manufacture of recombinant 
products, E-Coli, yeast and mammalian cells. We are the only Indian company who is 
manufacturing in India while others are importing. [For other] products like Hepatitis 
vaccine we have the largest brand and third is recombinant insulin. We will also have a 
very strong pipeline for different recombinant products. Bio-generics will be the first and 
then there will be second generations and also monoclonal antibodies”. 
 
Biotechnology is Wockhardt's R&D thrust area and with three exclusive products in the 
market, the company has been the front runner in biotechnology research. From the 
early 1990s the company has spent 20 -30% of its total research budget on biotech 
R&D. In 1995 Wockhardt formed a joint venture with the German firm Rhein Biotech to 
manufacture hepatitis B vaccine and in 2000 the company launched its first biotech 
product, a hepatitis B vaccine called Biovac-B. This joint venture helped the company to 
develop manpower trained in biotechnology R&D and provided access to crucial know-
how. In 2002 Wockhardt acquired Rhein Biopharm and got hold of co-exclusive licence 
on Rhein Biotech's Hansenula polymorpha technology for the production of Hepatitis-B 
vaccine in India.  
 
In 2001 Wockhardt indigenously produced a drug called erythropoietin (EPO) for severe 
anaemia.  In India, erythropoietin was produced for the first time using genetic 
engineering methods. However for Wockhardt an important milestone in biotech R&D 
came with development of human insulin. In 2003, Wockhardt launched a human insulin 
named Wosulin. Wosulin become the first Human insulin to be made indigenously by an 
Indian company. At that time Wockhardt was only the fourth company in the world and 
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the first outside US and Europe to develop, manufacture and market this life saving drug 
used in diabetes.   
 
In 2010 Wockhardt entered into a strategic alliance with Sheffield Bio-Science of the US, 
which will exclusively distribute Wockhardt’s recombinant insulin in cell culture markets 
globally. 

5.4 Biocon 
 
Biocon, established in 1978 by Kiran Muuzumdar Shah, is a fully integrated 
biopharmaceutical company focused on biopharmaceuticals, custom research and 
clinical research. Located in Bangalore, India, Biocon has two subsidiaries, Syngene, a 
custom research organization, and Clinigene, a clinical research organization. Biocon’s 
presence straddles four main therapeutic areas: Diabetology, Cardiology, Nephrology 
and Oncology. 
 
Biocon was the first Indian company to manufacture and export enzymes to the US and 
Europe in 1979. It was primarily focussed on enzyme manufacturing from 1978 to 1997. 
In 1989, Biocon was acquired by Unilever. In the mid-1990s, Kiran Mazumdar-Shaw 
decided to focus on biopharmaceuticals rather than enzymes and in 2001 it started 
manufacturing insulin. After the 2001 patent expiration on Lovastatin, one of the earliest 
cholesterol blockers, Biocon got permission from Indian regulators to sell the generic in 
India. In 2001 Biocon became the first Indian company to get U.S. Food & Drug 
Administration permission to sell Lovastatin in the U.S (Egan, 2004).  
 
In 2010 Biocon and Pfizer entered into a global agreement for the worldwide 
commercialization of Biocon’s biosimilar insulin and insulin analog products. Biocon set 
out to establish a state-of-the-art biopharmaceutical manufacturing facility at BioXcell, a 
custom built biotechnology park and ecosystem in Malaysia. The worldwide 
requirements for Biocon’s biosimilar versions of insulin and insulin analog products 
would be catered for by Biocon’s existing facility in India and from the Malaysian facility 
when the facility becomes operational. 
 
5.5 Cipla 
 
Cipla or ‘Chemical, Industrial and Pharmaceutical Laboratories Ltd’ was started by Dr. 
Hamied in 1935. Over the last five decades Cipla has developed extensive capabilities in 
reverse engineering small molecules and has emerged as a cheap supplier of generic 
products to Indian domestic as well as advanced markets. From early 1990s, Cipla was 
among the top five companies in the Indian pharmaceutical sector. Post 2000 Cipla 
overtook other Indian and MNC firms to become the largest pharmaceutical company in 
the domestic market. 
 
Cipla gained prominence globally with its offer to sell HIV drugs to African countries at 
much lower prices than MNC firms. This created significant controversy and forced MNC 
firms to lower their prices for African markets. Post 2000 Cipla is targeting its attention at 
the global biosimilar markets and started entering into collaborations for biotechnology 
capability development. With no expertise in reverse engineering of large molecules or 
proteins, Cipla hit a roadblock and entered into strategic alliances in order to build its 
biologic capabilities. In 2004 Cipla had formed a 50:50 joint venture with Avesta 
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Biotherapeutics and Research (ABRPL) —between its group company Meditab 
Specialties and Bangalore-based Avestha Gengraine Technologies (Avesthagen) to 
develop about a dozen biosimilar drugs, mainly to treat cancer and heart conditions. 
.However, the joint venture failed to meet its research targets and Cipla is now forced to 
look at alternate options (Business Standard, 2010). According to Economic Times 
(2010) Cipla aims to buy a 40 percent stake in Goa-based Mab Pharm and a 25 percent 
stake in Bio Mabs, Shanghai to gain the rights to sell biosimilars in India.  
 
Cipla is targeting three of Roche's top biologics: Avastin, Herceptin and Enbrel. These 
account for $19 billion in annual revenue. Cipla is establishing a manufacturing plant to 
produce biosimilars in Goa, and the company expects to launch its first biosimilar 
products in early 2012. 
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6.  Conclusions and areas for further study 
 
Increasing demand for biologics for new and improved disease treatments alongside the 
demand for more cost effective treatment has created a growing market for biosimilars in 
both developed and developing countries. This review highlights the favourable position 
for suppliers that aim to provide biosimilars for markets regulated by authorities other 
than the FDA. Most suppliers for biosimilars are based in the Asia-Pacific region and in 
Europe. A number of strategies are being developed by innovating companies and 
emerging suppliers to develop capabilities in order to compete in the biosimilars market, 
including investment, partnerships, mergers and acquisitions. At the same time there are 
challenges in addressing the high costs of regulatory compliance, capital investment for 
new biological production methods and innovating to improve analytical methods and 
product differentiation. Risks still remain with costs of litigation stemming from regulation 
(particularly in the area of data exclusivity) that is still evolving.  
 
Section 5 has illustrated the promise of the Indian pharmaceutical sector in particular, 
where capabilities are developing in gene manipulation and fermentation. Other key 
areas however, such as bioprocess development and cell-line development, are absent. 
The Indian pharmaceutical sector, in the attempt to pursue biosimilars is likely to face the 
challenges of developing process R&D expertise in biotechnological, availability of 
skilled human resource in biochemistry and medicinal biology and developing financially 
robust strategies to operate in uncertain regulatory environments in advanced countries.   
 
Much of the work on the biosimilar market and sector has been written by those who are 
closely linked to industry and the literature therefore is widely reflective of industry 
perspectives. Articles are short and offer opinions and news, without offering in-depth 
critical analysis (with the exception of law-based articles that have examined the 
precarious situation of the FDA and US regulation). It appears that in the last two years 
there has been very little published in social science journals which is not of the opinion 
or news kind. In particular we find that the questions about the wider innovation system, 
impact on society or the effect of national and regional government incentives on the 
structure and capabilities of the industrial sector, are not asked, nor answered.   
 
Capabilities of innovation systems to deliver biosimilars as a solution to the health 
system problems that contribute to worsening social welfare, poverty and injustice, are 
vital to examine at this time. Capabilities are impacted by external factors such as 
economic stability, political harmony, government economic and industrial policy, and 
specific regulatory frameworks. Capabilities are also created by factors internal to the 
firm environment, for example; the development of personnel, the ability to learn and 
rearrange competences in order to respond to the market and external stimuli and the 
ability to innovate. For a national innovation system to respond to this new biosimilar 
market, the system as a whole needs to have adequate links between actors and a 
strong institutional framework for knowledge flow and learning. These are the gaps in the 
current literature which require further study. 
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